NEW YORK (GenomeWeb) – Investment bank Rodman & Renshaw has initiated coverage of Nanosphere at a Buy rating and a 12-month price target of $2 per share.

The bank believes that Nanosphere's Verigene infectious disease identification system has the potential for significant sales growth. Rodman analyst Yi Chen wrote that the Verigene system and test panels are differentiated from competing systems because it's based on gold nanoparticle technology and doesn't use PCR.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.